Ken Griffin Galecto, Inc. Call Options Transaction History

Citadel Advisors LLC

  • $483 Billion
  • Q2 2024

Call Options

5 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q2 2024

Aug 14, 2024
SELL
$0.47 - $0.76 $14,335 - $23,180
-30,500 Reduced 99.67%
100 $0
Q1 2024

May 15, 2024
BUY
$0.6 - $0.89 $16,980 - $25,187
28,300 Added 1230.43%
30,600 $23,000
Q4 2023

Feb 14, 2024
BUY
$0.52 - $0.78 $1,196 - $1,794
2,300 New
2,300 $1,000
Q2 2023

Aug 14, 2023
BUY
$1.68 - $2.84 $3,360 - $5,680
2,000 Added 22.22%
11,000 $27,000
Q1 2023

May 15, 2023
BUY
$1.21 - $2.86 $10,890 - $25,740
9,000 New
9,000 $17,000

Others Institutions Holding GLTO

# of Institutions
21
Shares Held
1.52M
Call Options Held
100
Put Options Held
100
View Full List

About Galecto, Inc.

GLTO Quotes by TradingView
  • Ticker GLTO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,395,700
  • Market Cap $186M
  • Description
  • Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clini...
More about GLTO
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email